{"classes":[{"categories":[{"measurements":[{"comment":"Data could not be calculated as the values were below the limit of quantification.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Data could not be calculated as the values were below the limit of quantification.","groupId":"OG001","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Saliva; 30 days post last dose"},{"categories":[{"measurements":[{"comment":"Data could not be calculated as the values were below the limit of quantification.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Data could not be calculated as the values were below the limit of quantification.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Data could not be calculated as the values were below the limit of quantification.","groupId":"OG002","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"Saliva; 45 days post last dose"},{"categories":[{"measurements":[{"comment":"Data could not be calculated as the values were below the limit of quantification.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Data could not be calculated as the values were below the limit of quantification.","groupId":"OG001","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Saliva; 60 days post last dose"},{"categories":[{"measurements":[{"comment":"Data could not be calculated as the values were below the limit of quantification.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Data could not be calculated as the values were below the limit of quantification.","groupId":"OG001","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Skin swab; 30 days post last dose"},{"categories":[{"measurements":[{"comment":"Data could not be calculated as the values were below the limit of quantification.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Data could not be calculated as the values were below the limit of quantification.","groupId":"OG001","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Urine; 30 days post last dose"},{"categories":[{"measurements":[{"comment":"Data could not be calculated as the values were below the limit of quantification.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Data could not be calculated as the values were below the limit of quantification.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Data could not be calculated as the values were below the limit of quantification.","groupId":"OG002","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"Urine; 45 days post last dose"},{"categories":[{"measurements":[{"comment":"Data could not be calculated as the values were below the limit of quantification.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Data could not be calculated as the values were below the limit of quantification.","groupId":"OG001","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Urine; 60 days post last dose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"Viral titers in each matrix (saliva, urine and skin swabs \\[30 days post last dose only\\]) at 30, 45 and 60 days after last dose of study treatment is reported in this outcome measure.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with any advanced or metastatic solid tumor indications with approved therapies using immune checkpoint inhibitors or anti-vascular endothelial growth factor agents were administered PF-07263689 at a dose 2\\*10\\^8 plaque forming unit (PFU) once weekly for 4 weeks as an intravenous (IV) push. Participants were followed up for up to 90 days post-last dose of study treatment. Participants were followed up for survival until death, withdrawal of consent, or end of the study.","id":"OG000","title":"Part 1A PF-07263689 2*10^8 PFU"},{"description":"Participants with any advanced or metastatic solid tumor indications with approved therapies using immune checkpoint inhibitors or anti-vascular endothelial growth factor agents were administered PF-07263689 at a dose 6\\*10\\^8 PFU once weekly for 4 weeks as an IV push. Participants were followed up for up to 90 days post-last dose of study treatment. Participants were followed up for survival until death, withdrawal of consent, or end of the study.","id":"OG001","title":"Part 1A PF-07263689 6*10^8 PFU"},{"description":"Participants with any advanced or metastatic solid tumor indications with approved therapies using immune checkpoint inhibitors or anti-vascular endothelial growth factor agents were administered PF-07263689 at a dose 20\\*10\\^8 PFU once weekly for 4 weeks as an IV push. Participants were followed up for up to 90 days post-last dose of study treatment. Participants were followed up for survival until death, withdrawal of consent, or end of the study.","id":"OG002","title":"Part 1A PF-07263689 20*10^8PFU"}],"paramType":"MEAN","populationDescription":"Vector Shedding Analysis Set included all enrolled participants who were treated and had at least 1 analyte concentration above the lower limit of quantitation. Data is not reported for Part 1b as no participants were enrolled and data was not collected. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure and contributed data to the table and 'Number Analyzed' signifies participants evaluable for the specified time points.","reportingStatus":"POSTED","timeFrame":"At 30, 45 and 60 days post last dose of study treatment (up to 24 days of treatment exposure)","title":"Part 1: Viral Titers in Saliva, Urine and Skin Swabs During 30, 45 and 60 Days After the Last PF-07263689 Dose","type":"SECONDARY","unitOfMeasure":"Copies per milliliter"}